Monitor upcoming quarterly earnings for initial commercial uptake metrics in the newly approved papillary-only segment. The expanded label creates a first-mover advantage in a large underserved population — watch for physician adoption rates and reimbursement coverage decisions.
Price Chart
Executive Summary
ImmunityBio announced FDA approval expanding ANKTIVA's indication to include BCG-unresponsive NMIBC patients with papillary-only tumors, covering the full spectrum of BCG-unresponsive NMIBC. This is the first FDA approval to include papillary-only tumors in this setting, significantly increasing the addressable patient population as papillary disease represents approximately 85% of NMIBC diagnoses.
Key Facts
- FDA expanded ANKTIVA (nogapendekin alfa inbakicept-pmln) plus BCG approval to include BCG-unresponsive NMIBC with papillary-only tumors
- First FDA approval to include BCG-unresponsive NMIBC with papillary-only tumors
- Papillary disease represents approximately 85% of the NMIBC patient population
- Expanded label now covers all patients with BCG-unresponsive NMIBC (CIS with/without papillary tumors, and papillary-only tumors)
- Approval based on QUILT-3.032 trial data: 62% of 77 patients achieved complete response; among responders, 58% maintained response for at least 12 months and 40% for at least 24 months
- Builds on prior April 2024 FDA approval for BCG-unresponsive NMIBC with CIS
Financial Impact
Significant expansion of addressable U.S. patient population — papillary-only tumors represent ~85% of NMIBC cases, adding a large new patient segment beyond the prior CIS-only indication. No specific revenue or market size figures provided in the filing.
Risk Factors
- Commercial adoption may be slower than anticipated if physicians are hesitant to use ANKTIVA for papillary-only disease without long-term data specific to this subpopulation
- Reimbursement and formulary access challenges could limit patient access
- Competition from emerging therapies for BCG-unresponsive NMIBC could erode market share
- Post-marketing safety surveillance could reveal new adverse events
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-421820 |
| Document: d188887d8k.htm | 0001193125-26-421820 |
| Document: 0001193125-26-421820-index-headers.html | 0001193125-26-421820 |
| Document: 0001193125-26-421820-index.html | 0001193125-26-421820 |
| Document: 0001193125-26-421820.txt | 0001193125-26-421820 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $10.00 | awaiting T+60 | — | $7.81 (−21.90%) |
Aug 4, 2026 11w ago | 8-K | $6.95 | awaiting T+60 | — | $7.81 (+12.37%) |
Jul 6, 2026 16w ago | Insider Cluster | $8.76 $9.44 | ▲ +7.76% | ▲ +5.77% | $7.81 (−10.84%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.44 $8.52 | ▼ −9.75% | ▼ −12.54% | $7.81 (−17.27%) |
May 18, 2026 23w ago | 8-K | $7.76 $7.65 | ▼ −1.42% | ▼ −7.71% | $7.81 (+0.64%) |
Apr 9, 2026 28w ago | 8-K | $7.48 $8.91 | ▲ +19.12% | ▲ +8.34% | $7.81 (+4.41%) |
Apr 6, 2026 29w ago | 8-K | $7.08 $9.20 | ▲ +29.94% | ▲ +16.47% | $7.81 (+10.31%) |
Feb 28, 2026 34w ago | Institutional Cluster | $10.44 $7.92 | ▼ −24.14% | ▼ −33.46% | $7.81 (−25.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers